As human beings grow old, there are numerous diseases which affect them. Commonly known as old age diseases, these diseases will wait until you grow old for them to strike. They will make your old life unbearable. Old age diseases affect the health of the victim in old age, making it hard for them to enjoy their finals days. The impact is felt by the family members who have to bear the costs of looking at their beloved ones. Some of the common old age diseases include blood pressure, arthritis, cancer, and dementia among others. Read this article at Wikipedia.
Although there has been advanced methods of treating these conditions, the research which exists only take care of treating the symptoms instead of stopping the diseases from affecting human beings. No solution addresses the root causes of the challenges that face the medical industry. If the root causes are addressed, there would be no need to invest in methods which will only cure the symptoms which keep on recurring until such a time when the body can no longer bear the medicines. The lack of solutions that address the root causes of a disease is the reason the future looks bleak if there is no other method to address the issues.
Although we do not have a solution that is addressing the pertinent questions in the fight against old age diseases, there is hope that we could get a solution that works in the way would like. There is ongoing research spearheaded by Jason Hope and others that address the root cause of aging. If we have to fight old age diseases, we must start by looking at what causes aging. If aging is the cause of the diseases, then we must fight off the cause. Jason Hope believes that an anti-aging drug is the way to go if we want to find a solution that works.
Jason Hope is supporting an organization known as the SENS Research Foundation that is carrying out research that could come up with the first anti-aging drug in the history of humankind. Jason Hope has donated over $500,000 for this research.
Clay Siegall is a recognized professional in the genetics and biotechnology industry. He has significantly assisted in bettering cancer treatments. Siegall is one of Seattle Genetics’ co-founders and also serves as the CEO of the firm. He has joined efforts with research experts to develop great cures that can be used in cancer treatment since chemotherapies have serious side effects on the human body. Seattle Genetics entered the industry as an average biotechnology company, and it is currently recognized due to the positive impact that it has made in the pharmaceuticals sector. The company has advanced its technology to develop customized cures that can be used in the treatment of a particular individual.
Dr. Siegall was motivated to start creating cancer therapies after discovering the adverse effects of chemotherapies. His goal has been to develop drugs that do not cause harm to the human body. Some products of the biotechnology company are FDA-approved, and they have been commercialized in the United States and other parts of the globe. The firm currently makes profits that enable it to be sustainable. The initial growth of Seattle Genetics depended on money from investors. The IPO of the enterprise was held in 2001, and it made about $675 million from various funding programs.
Seattle Genetics has played a significant role in the success of Clay Siegall’s career. Before establishing the enterprise, he was employed by Bristol-Myers Squibb Pharmaceutical Research Institute and served the firm as from 1991 to 1997. He was a lead researcher at the National Institute of Health where he worked as from 1988 to 1991. Clay Siegall was also hired by the National Cancer Institute.
The growth of the Seattle Genetic in the pharmaceuticals industry was facilitated by the development of the antibody-drug conjugates technology (ADCs). The company has committed itself to developing the technology over the years, and it got an FDA approval in 2011 for a drug that is known as ADCETRIS. To date, Seattle Genetics has developed more than 20 ADCs, and it sells them in the international markets. The company manufactures its products internally and externally by working with companies such as Takeda Pharmaceutical Company, Bayer, and Genentech.